Trump Administration Will Fund New Research on Controversial Psychedelic Drug IbogaineNovember 13, 2026
Gun Rights Advocate Wants More Democrats on Board. What’s Standing in the Way? – Bearing ArmsNovember 13, 2026
Linda L. Hernandez on November 4, 2026 10:01 am I like the balance sheet here—less leverage than peers. Reply
Jennifer B. Martinez on November 4, 2026 10:17 am Good point. Watching costs and grades closely. Reply
Emma Z. Rodriguez on November 4, 2026 10:04 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Olivia T. Brown on November 4, 2026 10:05 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Lucas C. Thomas on November 4, 2026 10:05 am Interesting update on Mutilation, Torture, and Victory: A Soldier’s Fight for Life!. Curious how the grades will trend next quarter. Reply
Emma Miller on November 4, 2026 10:06 am Nice to see insider buying—usually a good signal in this space. Reply
Noah G. Miller on November 4, 2026 10:07 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Amelia Garcia on November 4, 2026 10:08 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Olivia Brown on November 4, 2026 10:09 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Ava L. Jones on November 4, 2026 10:09 am Exploration results look promising, but permitting will be the key risk. Reply
Ava Rodriguez on November 4, 2026 10:10 am I like the balance sheet here—less leverage than peers. Reply
Mary Martin on November 4, 2026 10:10 am Interesting update on Mutilation, Torture, and Victory: A Soldier’s Fight for Life!. Curious how the grades will trend next quarter. Reply
Linda D. Thomas on November 4, 2026 10:10 am Exploration results look promising, but permitting will be the key risk. Reply
Emma Jackson on November 4, 2026 10:10 am Exploration results look promising, but permitting will be the key risk. Reply
By JackCarrUSA
By JackCarrUSA
By JackCarrUSA
27 Comments
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Interesting update on Mutilation, Torture, and Victory: A Soldier’s Fight for Life!. Curious how the grades will trend next quarter.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Interesting update on Mutilation, Torture, and Victory: A Soldier’s Fight for Life!. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.